Stereotaxis (NYSE:STXS) today reported third-quarter results that missed on revenue. However, investors reacted positively to a list of positive news from the surgical robotics company. St. Louis–based Stereotaxis lost $5.3 million, or 7¢ per share, off $7.7 million in revenue for the quarter ended Sept. 30, 2022. It lost $5.0 million, or 7¢ per share, […]
GE offering $8.25 billion in notes to help finance GE HealthCare spinoff
GE (NYSE:GE) announced today that it is offering $8.25 billion in senior notes in connection with its planned spinoff of GE HealthCare. The spinoff remains on track to take place during the first week of January 2023. It’s common for companies spinning out of larger parents to start out with debt. For example, spine and […]
Steris sticks by EPS guidance amid additional currency headwinds
Steris (NYSE: STE) reported mixed third-quarter results, but it held the line on EPS guidance amid additional foreign currency headwinds. The provider of sterilization services and other infection prevention tech lost $315.2 million, or $3.15 per share, off $1.20 billion in revenue for the quarter ended Sept. 30, 2022. Steris swung to a loss versus […]
NuVasive reports mixed Q3 results, reduces guidance
NuVasive (Nasdaq:NUVA) reported third-quarter results that beat on EPS but missed on revenue, reducing its guidance amid macroeconomic headwinds. Investors reacted to yesterday evening’s news by sending NUVA shares down more than 1% to 36.84 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up […]
ZimVie sticks by its full-year guidance
ZimVie (Nasdaq:ZIMV) reported mixed third-quarter results but reaffirmed its full-year guidance. Many medical device companies have been tightening or reducing guidance amid the present macroeconomic headwinds. With ZimVie announcing yesterday evening that it was holding the line, investors reacted by sending ZIMV shares up more than 28% to $9.42 apiece in trading the next morning. […]
BD beats The Street in Q4 as Medical revenue grows nearly 6%
BD (NYSE:BDX) today reported fourth-quarter results that beat Wall Street expectations. However, its 2023 guidance is less than expected. The Franklin Lakes, New Jersey–based medtech giant earned $287 million, or 92¢ per share, off $4.76 billion in revenue during the quarter ended Sept. 30, 2022. The results represent a bottom-line gain of 8.6% on a […]
Surgalign plans layoffs
Surgalign (Nasdaq:SRGA) today announced a board-approved corporate restructuring plan that includes layoffs. The Deerfield, Illinois–based spine surgery tech company did not disclose how many jobs may be cut amid the planned streamlining and brand and product portfolio rationalization initiatives. As of Dec. 31, 2021, Surgalign had 231 employees, including 70 outside the U.S., according to […]
Siemens Healthineers plans to streamline its Diagnostics business
Siemens Healthineers plans to halve the number of diagnostic platforms it offers in coming years as it seeks to overcome supply chain and other external challenges. In its Q4 earning announcement today, the German medtech giant said the €1.5-billion-a-year Diagnostics business faces procurement and logistics challenges. Also, there are foreign currency headwinds and COVID-related lockdowns […]
Masimo stock down on supply chain, economic headwinds
Masimo (Nasdaq: MASI) reported third-quarter results that beat the consensus forecast on Wall Street — but it held down its Q4 guidance. “We delivered strong results in the third quarter, with revenue and earnings exceeding expectations. Our healthcare segment achieved double-digit constant currency growth, and our consumer non-healthcare segment reported another quarter of better-than-expected results. […]
Rewalk Robotics seeks reimbursement wins
Rewalk Robotics (Nasdaq: RWLK) today reported its third-quarter revenues were half what they were a year before, with losses widening. However, the robotic exoskeletons company is seeking to advance its technology through reimbursement wins in the U.S. and Germany. Early this month, Rewalk submitted its first case to Medicare Administrative Contractors (MACs) for coverage and […]
NeuroMetrix strategically launches Quell Fibromyalgia
NeuroMetrix (Nasdaq: NURO) announced the strategic launch of its Quell Fibromyalgia device through its Pathfinder Program. The move — announced yesterday — comes nearly 6 months after NeuroMetrix said it had received an FDA de novo authorization to use its Quell neuromodulation device to treat fibromyalgia symptoms. The Pathfinder Program starts Dec. 1. NeuroMetrix limited […]